Searched for
TRASTUZUMAB
AstraZeneca's Enhertu gets regulatory approval in India for first-line HER2-positive breast cancerAstraZeneca Pharma India has secured approval from India's drug regulator for its smart chemotherapy drug Enhertu. This allows for its impo...- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- Market bets on Aurobindo as Europe, US sales show uptickAurobindo Pharma stock is performing well. Sales in Europe are improving. New products are launching in the US. The company is also develop...
- AstraZeneca gets regulator's nod to market cancer drug in IndiaAstraZeneca Pharma has secured approval from India's drug regulator for its cancer treatment Trastuzumab Deruxtecan. This drug is now appro...
- Glenmark inks pact with Hengrui Pharma for cancer therapy Trastuzumab RezetecanGlenmark Pharmaceuticals has partnered with Hengrui Pharma, securing exclusive rights to develop and commercialize Trastuzumab Rezetecan gl...
- Glenmark Pharma slashes price of breast cancer drug TrastuzumabTrastuzumab is used in the treatment of a particular type of breast cancer -- HER2-positive, and the company markets its version in India u...
- Dr. Reddy's inks pact with Singapore firm Prestige BioPharma to commercialise Trastuzumab biosimilar in select countriesHyderabad, Dec 9- Prestige BioPharma Ltd, a Singapore-based firm and Dr. Reddy's Laboratories Ltd., on Thursday announced that the two comp...
- Mylan-Biocon's breast cancer biosimilar gets ANVISA nodBiosimilar trastuzumab, indicated for breast cancer treatment, has been co-developed by Biocon and Mylan.
- Biocon surges 14% on USFDA approval to biosimilar drugWith annual sales of $3.16 billion globally, Trastuzumab is expected to touch nearly $10 billion by 2020.
- Breast cancer biosimilar approval delayed as US FDA reviews additional information by Biocon, MylanBiocon and Mylan have together developed the trastuzumab biosimilar, which is a copy of a complex biologic drug developed by Swiss biotech ...
- Roche, Emcure may end pact to make 2 blockbuster drugsEmcure is still the distributor for those two drugs in India. Roche had handed out the manufacturing and marketing of trastuzumab and ritux...
- Delhi HC asks government if it approved Biocon’s trastuzumab for three cancersBiosimilars are copies of complex drugs based on living cells. They are different from chemical-based generic drugs, which are 'identical' ...
- USFDA accepts Mylan's application for proposed biosimilar TrastuzumabThis is Mylan and Biocon's "first US regulatory submission through the 351(k) pathway and reinforces the strength of collaboration."
- Mylan and Biocon make USFDA submission for proposed biosimilar trastuzumabThe submitted BLA includes a comprehensive package of analytical similarity, nonclinical and clinical data that consists of two pharmacokin...
- Biocon shares surge over 3% as EMA accepts review of biosimilar TrastuzumabTrastuzumab is used to treat certain breast and gastric cancers. At 11:05 am, shares of the company were trading at Rs 894 apiece, up 3.28%...
- EMA accepts Biocon and Mylan's regulatory submission for proposed breast cancer biosimilar drugBiocon and Mylan are engaged in a court battle in India against Swiss biotech firm Roche over marketing restrictions imposed on their trast...
- Biocon, Mylan likely to appeal Delhi HC ruling on Roche's cancer drug trastuzumabThe order, which raised questions on the processes followed by the Indian drug controller in approving such drugs, could also affect the av...
- Biocon gets DCGI nod to market biosimilar trastuzumab in IndiaBiocon today said it has received approval from the Indian drug regulator to market its biosimilar trastuzumab developed jointly with Mylan.
- Biocon gets DCGI nod to market biosimilar trastuzumab in IndiaBiocon said it has received approval to market its biosimilar trastuzumab developed jointly with Mylan for treating breast cancer.
- Compulsory licence: Health Min submits details of ' trastuzumab' to DIPPCL can be invoked by a national government allowing a company to produce a patented product without the consent of the patent owner in publ...
Load More
